0.9% sodium chloride (normal saline)
Sponsors
Immunabs Inc., Daiichi Sankyo, Renibus Therapeutics, Inc., siRNAgen Therapeutics Inc., National and Kapodistrian University of Athens
Conditions
COVID-19Generalized Myasthenia Gravis and Ocular Myasthenia GravisGenitourinary Syndrome of Menopause (GSM)Idiopathic Pulmonary FibrosisParkinson's Disease
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
RecruitingNCT07407543
Start: 2026-01-05End: 2027-04-30Target: 30Updated: 2026-02-12
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Not yet recruitingCTIS2025-522406-20-00
Target: 51Updated: 2026-02-18
Phase 2
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
CompletedNCT00623363
Start: 2007-07-13End: 2008-07-17Updated: 2021-03-11
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
TerminatedNCT04364763
Start: 2020-08-05End: 2021-09-30Updated: 2023-03-29